Ardsley Advisory Partners’s Immunomedics Inc IMMU Stock Holding History

Ardsley Advisory Partners’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-140,000	Closed	-$2.96M	–	182
2019 Q4	$2.96M	Buy	+140,000	New	+$2.47M	0.47%	43
2019 Q1	–	Sell	-285,000	Closed	-$4.07M	–	155
2018 Q4	$4.07M	Buy	285,000 +12,500	+5%	+$248K	1.02%	31
2018 Q3	$5.68M	Sell	272,500 -2,500	-0.9%	-$59.2K	0.76%	40
2018 Q2	$6.51M	Buy	275,000 +10,000	+4%	+$201K	0.98%	39
2018 Q1	$3.87M	Buy	265,000 +40,000	+18%	+$654K	0.58%	49
2017 Q4	$3.64M	Buy	+225,000	New	+$2.66M	0.44%	49
2017 Q2	–	Sell	-10,000	Closed	-$65K	–	197
2017 Q1	$65K	Buy	+10,000	New	+$50.7K	0.01%	148

Other funds holding IMMU

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ardsley Advisory Partners's IMMU Position: Q1 2020 in Review

Ardsley Advisory Partners sold out of Immunomedics Inc (IMMU) in Q1 2020, closing a stake of 140,000 shares — an estimated $2.96M sold.

Ardsley Advisory Partners first reported a position in IMMU in Q1 2017 and held it in 7 quarters. The position peaked at $6.51M in Q2 2018. 220 funds tracked by Wall St. Rank hold IMMU as of Q1 2020.

Ardsley Advisory Partners reported no remaining Immunomedics Inc position as of Q1 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 140,000 Immunomedics Inc shares in Q1 2020, an estimated $2.96M.
Ardsley Advisory Partners first reported a position in Immunomedics Inc in Q1 2017 and held it in 7 quarters.
Ardsley Advisory Partners's Immunomedics Inc position peaked at $6.51M in Q2 2018.
220 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2020.

Based on Ardsley Advisory Partners's 13F filing for Q1 2020, filed 15 May 2020.